Bristol-Myers Squibb | BMY - Pre Tax Profit


Bristol-Myers Squibb reported $4.99B in Pre-Tax Profit for its fiscal quarter ending in June of 2026.





Pre Tax Profit Change Date
AbbVie USD 7.87B 253M Sep/2026
Abbott USD 2.92B 535M Sep/2026
ALKERMES USD -1.88M 60.05M Jun/2026
Amgen USD 4.19B 1.42B Sep/2026
AstraZeneca USD 5.49B 684.4M Sep/2026
Biogen USD 647.3M 269.6M Jun/2026
Bristol-Myers Squibb USD 4.99B 1.75B Jun/2026
Coherus Biosciences USD -46.35M 90.86M Dec/2025
Drreddys Laboratories INR 12.28B 10.28B Sep/2026
Eli Lilly USD 8.79B 457M Sep/2026
Gilead Sciences USD -7.53B 10.11B Jun/2026
GlaxoSmithKline GBP 2.68B 532M Jun/2026
J&J USD 7.67B 988M Sep/2026
Medtronic USD 2.26B 190M Jun/2026
Merck USD -683M 2.85B Jun/2026
Novartis USD 4.27B 430M Jun/2026
Novo Nordisk DKK 33.8B 3.23B Jun/2025
Perrigo USD 105.4M 513.9M Jun/2026
Pfizer USD 3.38B 4.04B Sep/2026
Phibro Animal Health USD 38.62M 1.26M Dec/2025
Prestige Brands USD 64.77M 2.96M Mar/2026
Regeneron Pharmaceuticals USD 1.53B 696.6M Jun/2026
Roche Holding CHF 11.17B 6.38B Jun/2026
Sanofi EUR 5.28B 4.44B Sep/2026
Sanofi EUR 6.07B 5.23B Sep/2026
United Therapeutics USD 372.7M 54.4M Jun/2026
Zoetis USD 758M 3M Mar/2026